{"gene":"CXCL9","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1996,"finding":"CXCL9 (Mig) signals through the CXCR3 receptor, a G-protein coupled receptor selectively expressed on IL-2-activated T lymphocytes; binding mediates Ca2+ mobilization and chemotaxis specifically in activated T cells but not in resting T cells, B cells, monocytes, or granulocytes.","method":"Receptor cloning, Ca2+ flux assay, chemotaxis assay, expression profiling by Northern/flow cytometry","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — receptor cloned and functionally characterized with multiple orthogonal methods (Ca2+ mobilization, chemotaxis, selectivity panel); replicated by independent groups","pmids":["9064356"],"is_preprint":false},{"year":1995,"finding":"Recombinant human CXCL9 (Mig) induces transient elevation of intracellular Ca2+ and is chemotactic for activated T lymphocytes and tumor-infiltrating lymphocytes, but not for neutrophils or monocytes; secreted CXCL9 exists as multiple species due to proteolytic cleavage at basic carboxy-terminal residues occurring intracellularly before secretion, and carboxy-terminal truncation reduces specific activity.","method":"CHO cell expression/purification, Ca2+ flux assay, modified Boyden chamber chemotaxis assay, SDS-PAGE, N-terminal sequencing","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — recombinant protein biochemistry with multiple orthogonal assays; activity-structure relationship established by truncation analysis","pmids":["7595201"],"is_preprint":false},{"year":1993,"finding":"CXCL9 (HuMig) is induced in human monocytic cells (THP-1) and peripheral blood mononuclear cells by IFN-γ but not by IFN-α or LPS, establishing IFN-γ as the primary transcriptional inducer.","method":"cDNA library screening, Northern blot, cytokine stimulation assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single lab, multiple stimuli tested with Northern blot, clearly delineating IFN-γ specificity","pmids":["8476424"],"is_preprint":false},{"year":1997,"finding":"CXCL9 and IP-10/CXCL10 share the CXCR3 receptor, show reciprocal desensitization on activated T cells, inhibit neovascularization, inhibit hematopoietic progenitor cells, and exert anti-tumor effects in vitro and in vivo.","method":"Receptor cross-desensitization assay, in vitro angiogenesis inhibition assay, in vivo tumor models","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple activities demonstrated with orthogonal methods in a single review/experimental paper, replicated across two chemokines","pmids":["9060447"],"is_preprint":false},{"year":2009,"finding":"CXCL9 exerts direct antifibrotic effects on human hepatic stellate cells (LX-2) by suppressing collagen production; CXCR3-deficient mice show increased liver fibrosis associated with decreased intrahepatic IFN-γ-positive T cells and reduced IFN-γ mRNA, indicating that CXCL9-CXCR3 regulates Th1-associated antifibrotic immune pathways in the liver.","method":"In vitro stellate cell stimulation (collagen production assay), CXCR3 knockout mouse model of liver fibrosis, intrahepatic immune cell subset analysis, IFN-γ mRNA measurement","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro direct cellular assay plus in vivo KO model with defined cellular and molecular phenotype readouts","pmids":["19344719"],"is_preprint":false},{"year":2016,"finding":"Osteoblast-secreted CXCL9 acts as an angiostatic factor by interacting with VEGF and preventing its binding to endothelial cells and osteoblasts, thereby abrogating angiogenesis and osteogenesis in bone marrow; mTORC1 activates CXCL9 expression in osteoblasts by transcriptional upregulation of STAT1, which increases STAT1 binding to the Cxcl9 promoter.","method":"Mouse bone marrow model, in vitro VEGF binding competition assay, STAT1 ChIP assay, mTORC1 signaling inhibition","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic pathway defined by multiple orthogonal methods: protein interaction (VEGF binding), promoter ChIP, in vivo and in vitro loss-of-function","pmids":["27966526"],"is_preprint":false},{"year":2002,"finding":"CXCL9 (MIG) plays a functionally required role in CD4+ T lymphocyte recruitment in cardiac allograft vasculopathy (CAV); macrophages (MOMA-2+) are the predominant source of CXCL9 in this context, and antibody neutralization of CXCL9 significantly reduces CD4+ T cell infiltration and intimal thickening.","method":"MHC II-mismatched murine cardiac transplant model, antibody neutralization, immunohistochemistry, gene expression profiling","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo neutralization with defined cellular phenotype, macrophage source identified by immunostaining, replicated mechanistic conclusion","pmids":["12368204"],"is_preprint":false},{"year":2003,"finding":"CXCL9 (MIG) and CXCL10 (IP-10) are required for SLC/CCL21-mediated antitumor responses; in vivo depletion of either chemokine reduces antitumor efficacy, CXCR3+ T cell frequency, and CD11c+ DC accumulation at the tumor site, revealing interdependence among IFN-γ, CXCL9, and CXCL10 in antitumor immunity.","method":"In vivo antibody depletion/neutralization, flow cytometry, cytokine/chemokine measurement at tumor site","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo neutralization with defined cellular readouts, single lab","pmids":["12740040"],"is_preprint":false},{"year":2009,"finding":"Hepatitis B virus HBx protein induces CXCL9 (MIG) expression in a dose-dependent manner via direct NF-κB binding to the MIG promoter at position -147, as demonstrated by luciferase reporter, ChIP, and EMSA; increased CXCL9 protein levels enhance migration of peripheral blood lymphocytes, an effect blocked by NF-κB inhibition.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), chemotaxis assay, NF-κB inhibition","journal":"Virology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter mechanism established by three orthogonal molecular methods (luciferase, ChIP, EMSA) in single lab","pmids":["19157479"],"is_preprint":false},{"year":2002,"finding":"In the virus-infected liver (adenovirus hepatitis model), IFN-γ induces CXCL9 (MIG) and IP-10 in hepatocytes; optimal induction requires a co-stimulatory signal from Fas cross-linking on hepatocytes; NK/T cells expressing NK1.1 and AsGM1 provide both signals; antibody-mediated ablation of NK/T cells inhibits IFN-γ and chemokine transcript induction. T cell (but not NK cell) chemotaxis by hepatocyte supernatants was abrogated by anti-Mig and anti-Crg-2 antibodies.","method":"Murine adenovirus hepatitis model, NK/T cell depletion, anti-Fas antibody injection, neutralizing antibody chemotaxis inhibition assay","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo depletion and in vitro neutralization with defined cellular/molecular readouts, single lab","pmids":["12473267"],"is_preprint":false},{"year":2002,"finding":"IFN-γ plus TNF-α induces CXCL9 (MIG) expression in human mesangial cells; NO donors suppress this induction through cGMP-independent inhibition of NF-κB activation, as shown by EMSA.","method":"Primary human mesangial cell culture, cytokine stimulation, EMSA, NO donor treatment, immunostaining","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA identifies NF-κB as the transcriptional mediator; mechanistic pathway established by pharmacological inhibition and molecular assay, single lab","pmids":["11752021"],"is_preprint":false},{"year":1999,"finding":"CXCL9 (MIG) and CXCL10 (IP-10), signaling through CXCR3 expressed on mesangial cells, directly induce proliferation of human mesangial cells, revealing a non-immune direct cellular effect of these chemokines.","method":"CXCR3 expression by flow cytometry, Ca2+ flux assay, cell proliferation assay with recombinant chemokines","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional receptor expression confirmed by flow cytometry, proliferative effect directly demonstrated in vitro, single lab","pmids":["10589690"],"is_preprint":false},{"year":2010,"finding":"M. tuberculosis inhibits IFN-γ-induced CXCL9 (MIG) transcription by disrupting STAT1α binding to cis-regulatory elements in the MIG promoter, partially via NF-κB and p38 MAPK pathways; paradoxically, combined IFN-γ and MTB stimulation increases MIG protein through post-transcriptional mechanisms involving NF-κB and p38 MAPK.","method":"STAT1 EMSA on MIG promoter elements, kinase inhibitor studies, RT-PCR, ELISA protein measurement","journal":"Tuberculosis (Edinburgh, Scotland)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA identifies transcriptional mechanism, inhibitor studies delineate signaling pathway, single lab","pmids":["21167783"],"is_preprint":false},{"year":2016,"finding":"Progranulin (PGRN) inhibits TNF- and IFN-γ-induced CXCL9 and CXCL10 expression, and this inhibitory effect depends on TNFR1 signaling, as demonstrated by gene array analysis in PGRN-null mice and recombinant PGRN protein treatment experiments.","method":"Gene array on PGRN KO vs. WT CD4+ T cells, recombinant PGRN treatment, TNFR1-dependent rescue experiments, dermatitis model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse plus recombinant protein rescue, TNFR1 dependency shown, single lab","pmids":["26892362"],"is_preprint":false},{"year":2015,"finding":"IL-27 induces CXCL9, CXCL10, and CXCL11 expression in hepatic cells in a STAT1-dependent manner; during ConA-induced hepatitis, IL-27 and IFN-γ cooperatively regulate CXCR3 ligand expression, with IFN-γ KO abolishing upregulation.","method":"In vitro cytokine stimulation (human hepatic cell lines and primary cells), in vivo ConA hepatitis model, IL-27 neutralization, IFN-γ KO mice, RT-PCR, ELISA","journal":"Journal of molecular medicine (Berlin, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo with KO and neutralization, STAT1-dependence established, single lab","pmids":["26199110"],"is_preprint":false},{"year":2019,"finding":"Macrophages are the predominant cellular source of CXCL9 following dual PD-1/CTLA-4 immune checkpoint blockade; macrophage depletion abrogates CD8+ T cell infiltration and therapeutic efficacy, establishing macrophage-derived CXCL9 as functionally required for ICB antitumor responses.","method":"NanoString analysis, flow cytometry, cytometric bead array, antibody depletion, single-cell RNA-seq, murine tumor models","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — macrophage depletion with defined functional readout, validated in both murine models and human patient scRNA-seq data, multiple orthogonal methods","pmids":["31636098"],"is_preprint":false},{"year":2022,"finding":"CXCL9 directly induces Col1a1 (collagen type I) mRNA expression in murine fibroblasts via CXCR3; fibrosis in a bleomycin skin model is dependent on CXCL9 and CXCR3 (not CXCL10), as shown by chemokine- and receptor-deficient mouse experiments.","method":"Cxcl9-KO, Cxcl10-KO, Cxcr3-KO mouse bleomycin fibrosis model, recombinant CXCL9 stimulation of fibroblasts, Col1a1 mRNA quantification, REX3 reporter mice","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — KO mice with specific phenotype readout, direct recombinant protein stimulation assay, chemokine-specific (CXCL9 not CXCL10) distinction established","pmids":["36708947"],"is_preprint":false},{"year":2022,"finding":"CXCL9 promotes Th17 cell proliferation and skews the Treg/Th17 balance toward Th17 in a JNK-dependent manner; AAV-mediated silencing of CXCL9 in a murine MASH model reduces Th17 frequency and phospho-JNK levels, while CXCL9 overexpression has the opposite effect.","method":"Recombinant adeno-associated virus gene transfer/silencing, T cell differentiation assays, phospho-JNK western blot, JNK inhibitor experiments, murine MASH model","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo AAV manipulation with defined cellular phenotype plus in vitro mechanistic follow-up, single lab","pmids":["34461107"],"is_preprint":false},{"year":2022,"finding":"CXCL9 signaling through CXCR3 activates the JAK1/STAT2 pathway in triple-negative breast cancer cells; CXCL9 overexpression increases JAK1/STAT2 phosphorylation as shown by western blot.","method":"CXCL9 overexpression in MDA-MB-231 cells, western blot for JAK1/STAT2 phosphorylation","journal":"Cancer immunology, immunotherapy : CII","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (western blot) in single cell line, no receptor knockdown validation","pmids":["36472587"],"is_preprint":false},{"year":2018,"finding":"CXCL9/10/11 signaling through CXCR3 upregulates PD-L1 expression in gastric cancer cells by activating STAT3 and Akt (PI3K-Akt) pathways; blocking CXCR3 signaling abolishes PD-L1 upregulation and phosphorylation of STAT3 and Akt.","method":"Western blot, gastric cancer cell line treatment with recombinant CXCL9/10/11, CXCR3 blocking, in vivo tumor experiments","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor blocking plus pathway western blot in vitro and in vivo confirmation, single lab","pmids":["29690901"],"is_preprint":false},{"year":2022,"finding":"CXCL9 overexpression in murine ovarian cancer (ID8) models results in T-cell accumulation, delayed ascites formation, and improved survival dependent on adaptive immune function; in ICB-resistant models, CXCL9 is sufficient to enable successful anti-PD-L1 therapy.","method":"Murine ovarian cancer models with CXCL9 overexpression, immune depletion experiments, survival analysis, flow cytometry","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss/gain of function with defined cellular and survival readouts, single lab","pmids":["35314795"],"is_preprint":false},{"year":2022,"finding":"CXCL9 inhibits collagen deposition in human pulmonary arterial smooth muscle cells (hPASMCs) via CXCR3, and pharmacological NKT cell activation restores CXCL9 production and ameliorates vascular remodeling in a mouse PH/fibrosis model via the STAT1-CXCL9-CXCR3 axis; CXCL10 did not share this antifibrotic effect.","method":"NKT cell coculture with hPASMCs, secretome analysis, CXCL9 recombinant protein treatment, CXCR3 inhibition, murine PH/fibrosis model with pharmacological NKT activation (KRN7000)","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro recombinant protein assay plus in vivo pharmacological model with mechanistic readouts, single lab","pmids":["35763380"],"is_preprint":false},{"year":2016,"finding":"Prostaglandin E2 (a COX metabolite) acts as a negative regulator of CXCL9 secretion in ovarian cancer cell lines, while COX inhibition by indomethacin (but not celecoxib) significantly upregulates CXCL9; celecoxib suppresses NF-κB activation and inhibits CXCL9 release.","method":"Ovarian cancer cell line treatment with PGE2 and COX inhibitors, ELISA for CXCL9/CXCL10, NF-κB activation assay","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological manipulations with defined molecular readouts, single lab","pmids":["27490802"],"is_preprint":false},{"year":2024,"finding":"DPP-4 cleaves the two N-terminal amino acids of CXCL9, converting it into a CXCR3 competitive antagonist that retains binding but loses receptor activation; adding an N-terminal glutamine residue to CXCL9-Fc renders it a fully active CXCR3 agonist resistant to DPP-4 cleavage, as demonstrated by biochemical analysis and computational modeling.","method":"Biochemical DPP-4 cleavage assay, CXCR3 binding and activation assays, computational modeling, engineering of N-terminal glutamine variant","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay, receptor activation assay, and structure-activity engineering combined in single study","pmids":["40238455"],"is_preprint":false},{"year":2012,"finding":"IFN-γ-mediated immune stress imposed by T cells drives tumor cells to epigenetically lose CXCL9/Mig expression (immunoediting); Mig-deficient tumor variants show increased resistance to T cell-mediated immunity; CXCL10 expression does not compensate for absent CXCL9 antitumor function, indicating a non-redundant role for CXCL9.","method":"Methylcholanthrene-induced fibrosarcoma and melanoma models, in vivo T cell and IFN-γ immune stress experiments, chemokine expression analysis, tumor growth assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo immune stress model with defined molecular and cellular readouts, non-redundancy established by comparison with CXCL10-expressing variants, single lab","pmids":["23241877"],"is_preprint":false},{"year":2019,"finding":"Glucocorticoids suppress CXCL9 and CXCL10 expression directly in renal tubular epithelial cells (not in T cells), resulting in reduced CXCR3+CD4+ T cell recruitment to the inflamed kidney; this CXCL9/CXCL10-CXCR3 axis was identified as a target of glucocorticoid-mediated protection in crescentic glomerulonephritis.","method":"In vitro glucocorticoid treatment of renal tubular cells, experimental mouse crescentic glomerulonephritis model, single-cell analysis of kidney biopsies, T cell recruitment assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic in vitro + in vivo with cell-type specific dissection (tubular cells vs T cells), single lab","pmids":["36355429"],"is_preprint":false},{"year":2019,"finding":"Cxcl9 secreted by osteoblasts during osteogenic differentiation in MSC co-cultures inhibits angiogenesis by suppressing VEGF binding to endothelial cells; mTOR/STAT1 signaling activates Cxcl9 in osteoblasts; blocking this pathway with rapamycin reduces Cxcl9 and restores angiogenesis.","method":"MSC-HUVEC co-culture, VEGF binding assay, mTOR/STAT1 inhibition with rapamycin, Cxcl9 knockdown","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic manipulations (KD, inhibitor, binding assay) in co-culture model, single lab","pmids":["31550444"],"is_preprint":false},{"year":2024,"finding":"CXCL9, CXCL10, and CCL19 are synergistically required for T cell (CD8+) recruitment in lichen planus; keratinocytes and fibroblasts in LP lesions are identified as cellular sources; an in vitro migration assay demonstrated synergistic enhancement of CD8+ T cell recruitment by CCL19 combined with CXCL9 or CXCL10 beyond any individual cytokine.","method":"scRNA-seq on blood and skin, in vitro T cell migration assay with primary human T cells and recombinant cytokines","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — scRNA-seq cell source identification plus direct functional migration assay, single lab","pmids":["39190494"],"is_preprint":false},{"year":2024,"finding":"LIF (leukemia inhibitory factor) induced by HPV E6/E7 via NFκB suppresses CXCL9 expression in tumor-associated macrophages; LIF blockade promotes CXCL9 induction and CD8+ T cell infiltration, sensitizing tumors to immune checkpoint inhibitors.","method":"Primary pDC and macrophage cultures, LIF blockade experiments, syngeneic animal models, patient-derived models, flow cytometry for CD8+ T cells","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — macrophage-specific CXCL9 suppression by LIF demonstrated in vitro and in vivo, pathway (E6/E7 → NFκB → LIF → CXCL9 suppression) established, single lab","pmids":["39078728"],"is_preprint":false},{"year":2024,"finding":"HIF-1α suppresses CXCL9 (and CXCL10, CXCL11) expression in colorectal cancer; HIF-1α knockdown or overexpression respectively increases or decreases these chemokines in vitro; in vivo BIRC2/HIF-1α inhibition promotes CD8+ T cell infiltration via the CXCL9/CXCL10/CXCL11-CXCR3 axis, and this is reversed by CXCR3 neutralization.","method":"HIF-1α knockdown/overexpression in CRC cell lines, CXCR3 neutralizing antibody in vivo, xenograft/syngeneic mouse models, flow cytometry","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional manipulation (KD and OE) plus in vivo CXCR3 neutralization epistasis, single lab","pmids":["38484558"],"is_preprint":false},{"year":2024,"finding":"EZH2 in tumor cells suppresses CXCL9 expression by repressing NF-κB-mediated CXCL9 transcriptional activation; EZH2 targeting restores CXCL9 expression and enhances CD8+ T cell infiltration into the tumor microenvironment of esophageal squamous cell carcinoma.","method":"EZH2 KD/inhibition, NF-κB pathway analysis, CXCL9 promoter regulation, CD8+ T cell infiltration assays in vivo and in vitro","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EZH2-NF-κB-CXCL9 transcriptional mechanism identified with functional downstream readout, single lab","pmids":["39702756"],"is_preprint":false},{"year":2016,"finding":"CXCL9 has direct antimicrobial activity against Streptococcus sanguinis and E. coli as demonstrated by radial diffusion assay; CXCL9 mRNA is absent in unstimulated oral keratinocytes but strongly induced by IFN-γ, whereas CXCL10 is constitutively expressed and enhanced by LPS.","method":"Radial diffusion antimicrobial assay, mRNA expression profiling by PCR with various stimuli (IFN-γ, LPS)","journal":"European journal of oral sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct antimicrobial assay with two bacterial species; differential induction pattern established, single lab","pmids":["27671889"],"is_preprint":false}],"current_model":"CXCL9 is an IFN-γ-inducible CXC chemokine that signals exclusively through the CXCR3 receptor (a Gαi-coupled GPCR) to mobilize intracellular Ca2+ and drive chemotaxis of activated CD4+ and CD8+ T cells, NK cells, and tumor-infiltrating lymphocytes, while leaving resting lymphocytes, neutrophils, and monocytes unresponsive; it is produced predominantly by macrophages, fibroblasts, and epithelial cells in inflammatory contexts, with its expression transcriptionally activated by IFN-γ via STAT1, augmented by TNF-α via NF-κB, suppressed by PGE2/COX, HIF-1α, EZH2, LIF, and MTB-mediated STAT1 displacement, and post-translationally truncated by DPP-4 (converting it to a CXCR3 antagonist); mechanistic studies have further defined direct antifibrotic actions in hepatic stellate cells, angiostatic activity through VEGF competition, pro-fibrotic Col1a1 induction in dermal fibroblasts via CXCR3, direct antimicrobial activity, and modulation of Th17/Treg balance via JNK signaling."},"narrative":{"mechanistic_narrative":"CXCL9 is an IFN-γ-inducible CXC chemokine that orchestrates the recruitment of activated T lymphocytes to inflamed and tumor tissues by signaling exclusively through the CXCR3 receptor, a G-protein-coupled receptor selectively expressed on IL-2-activated T cells, where ligand binding mobilizes intracellular Ca2+ and drives chemotaxis of activated T cells and tumor-infiltrating lymphocytes while leaving resting T cells, B cells, monocytes, and granulocytes unresponsive [PMID:9064356, PMID:7595201]. Its expression is transcriptionally driven by IFN-γ as the primary inducer [PMID:8476424], operating through STAT1 binding to the CXCL9 promoter [PMID:27966526, PMID:26199110] and through NF-κB, which can be engaged by viral HBx protein and is suppressed by nitric oxide donors [PMID:19157479, PMID:11752021]; this transcriptional output is repressed by HIF-1α, EZH2, LIF, prostaglandin E2/COX activity, and by M. tuberculosis-mediated displacement of STAT1 from cis-regulatory elements [PMID:21167783, PMID:27490802, PMID:39078728, PMID:38484558, PMID:39702756]. Functionally, CXCL9 is non-redundant with the co-receptor ligand CXCL10 in driving antitumor immunity: macrophage-derived CXCL9 is required for CD8+ T cell infiltration and the efficacy of immune checkpoint blockade, and tumors epigenetically silence CXCL9 to escape T cell-mediated control [PMID:31636098, PMID:23241877, PMID:39078728]. Beyond leukocyte trafficking, CXCL9 exerts direct, CXCR3-dependent effects on non-immune cells: it is angiostatic by competitively blocking VEGF binding to endothelial cells [PMID:27966526, PMID:31550444], it directly modulates fibrosis—suppressing collagen in hepatic stellate cells and pulmonary arterial smooth muscle cells yet inducing Col1a1 in dermal fibroblasts [PMID:19344719, PMID:36708947, PMID:35763380]—and it skews the Treg/Th17 balance toward Th17 in a JNK-dependent manner [PMID:34461107]. CXCL9 also possesses direct antimicrobial activity against bacteria [PMID:27671889]. Activity is governed post-translationally by N- and C-terminal proteolysis: C-terminal truncation at basic residues reduces specific activity [PMID:7595201], while DPP-4 cleavage of the two N-terminal residues converts CXCL9 into a CXCR3 competitive antagonist that retains binding but loses receptor activation [PMID:40238455].","teleology":[{"year":1993,"claim":"Establishing what stimulus controls CXCL9 expression was needed to place it in an immune pathway; demonstrating selective IFN-γ inducibility defined it as an interferon-effector chemokine.","evidence":"cDNA screening and Northern blot of IFN-γ-, IFN-α-, and LPS-stimulated human monocytic cells","pmids":["8476424"],"confidence":"Medium","gaps":["Did not identify the transcription factor mediating IFN-γ induction","Single cell type tested"]},{"year":1995,"claim":"Whether CXCL9 was a functional chemoattractant with cellular selectivity was unknown; recombinant protein assays showed it triggers Ca2+ flux and chemotaxis in activated/tumor-infiltrating T cells but not neutrophils or monocytes, and that C-terminal truncation tunes its activity.","evidence":"Recombinant CXCL9 from CHO cells, Ca2+ flux, Boyden chamber chemotaxis, SDS-PAGE and N-terminal sequencing","pmids":["7595201"],"confidence":"High","gaps":["Receptor identity not established here","Mechanism distinguishing activated from resting T cells unresolved"]},{"year":1996,"claim":"The receptor mediating CXCL9 action was unidentified; cloning CXCR3 and showing its selective expression on IL-2-activated T cells defined the receptor basis for CXCL9's leukocyte selectivity.","evidence":"Receptor cloning, Ca2+ flux, chemotaxis, and expression profiling across leukocyte subsets","pmids":["9064356"],"confidence":"High","gaps":["G-protein coupling details not dissected","Did not address shared ligand usage with other chemokines"]},{"year":1997,"claim":"Whether CXCL9 was redundant with CXCL10 and had non-chemotactic functions was open; demonstrating shared CXCR3 usage, reciprocal desensitization, and angiostatic/anti-tumor activity broadened its functional repertoire.","evidence":"Receptor cross-desensitization, in vitro angiogenesis inhibition, and in vivo tumor models","pmids":["9060447"],"confidence":"Medium","gaps":["Molecular mechanism of angiostasis not defined","Degree of non-redundancy with CXCL10 unresolved"]},{"year":2002,"claim":"Transcriptional control beyond IFN-γ and the cellular source in vivo were unclear; mesangial, cardiac allograft, and viral hepatitis studies identified NF-κB as a co-regulator, macrophages/hepatocytes as sources, and a functionally required role in CD4+ T cell recruitment.","evidence":"EMSA for NF-κB in cytokine-stimulated mesangial cells, antibody neutralization in murine cardiac transplant and adenovirus hepatitis models with immunostaining","pmids":["11752021","12368204","12473267"],"confidence":"Medium","gaps":["Quantitative contribution of NF-κB vs STAT1 not resolved","Co-stimulatory Fas requirement mechanism in hepatocytes incompletely defined"]},{"year":2003,"claim":"Whether CXCL9 cooperated with other chemokines in antitumor immunity was untested; depletion showed it is required alongside CXCL10 for CCL21-driven antitumor responses and CXCR3+ T cell/DC accumulation.","evidence":"In vivo antibody depletion, flow cytometry, and chemokine measurement at the tumor site","pmids":["12740040"],"confidence":"Medium","gaps":["Single tumor system","Did not separate CXCL9-specific from CXCL10-specific contributions"]},{"year":2009,"claim":"Direct non-immune cellular actions were unproven; stellate cell assays and CXCR3-KO mice established a direct antifibrotic effect and a Th1-associated antifibrotic axis, while HBx studies mapped NF-κB binding to a defined promoter position.","evidence":"LX-2 collagen assays, CXCR3-KO liver fibrosis model, and luciferase/ChIP/EMSA mapping of NF-κB at MIG promoter -147","pmids":["19344719","19157479"],"confidence":"High","gaps":["Downstream signaling driving collagen suppression not detailed","Direct vs IFN-γ-mediated contributions to the in vivo phenotype not fully separated"]},{"year":2012,"claim":"Whether CXCL9 was functionally non-redundant in tumor immunity was unsettled; immunoediting models showed tumors epigenetically lose CXCL9 under IFN-γ/T cell pressure and that CXCL10 cannot compensate.","evidence":"Methylcholanthrene fibrosarcoma/melanoma models with T cell and IFN-γ immune stress and chemokine expression analysis","pmids":["23241877"],"confidence":"Medium","gaps":["Epigenetic mechanism of silencing not molecularly defined","Single carcinogen-induced tumor lineage"]},{"year":2016,"claim":"The mechanism of angiostasis and additional regulatory inputs were unknown; osteoblast studies showed CXCL9 binds VEGF to block its receptor engagement under mTORC1/STAT1 control, PGE2/COX was identified as a negative regulator, and direct antimicrobial activity was demonstrated.","evidence":"VEGF binding competition assays, STAT1 ChIP, rapamycin inhibition in bone marrow/MSC models, COX inhibitor and ELISA studies, radial diffusion antimicrobial assays","pmids":["27966526","31550444","27490802","27671889"],"confidence":"High","gaps":["Structural basis of CXCL9-VEGF interaction not defined","Antimicrobial mechanism (membrane vs receptor) not established"]},{"year":2018,"claim":"Whether CXCR3 signaling in tumor cells had cell-intrinsic consequences was open; gastric cancer studies showed CXCR3 ligands upregulate PD-L1 via STAT3 and PI3K-Akt.","evidence":"Recombinant CXCL9/10/11 treatment with CXCR3 blocking and pathway western blots in vitro and in vivo","pmids":["29690901"],"confidence":"Medium","gaps":["CXCL9-specific contribution not isolated from CXCL10/11","Single cancer type"]},{"year":2019,"claim":"The therapeutically critical cellular source and a key suppressive input were undefined; checkpoint blockade and glucocorticoid studies identified macrophages as the required CXCL9 source for ICB efficacy and renal tubular epithelium as a glucocorticoid-suppressible source.","evidence":"Macrophage depletion with scRNA-seq in murine and human tumor data; cell-type-specific glucocorticoid treatment in renal tubular cells and crescentic glomerulonephritis models","pmids":["31636098","36355429"],"confidence":"High","gaps":["Transcriptional program distinguishing macrophage CXCL9 induction not fully mapped","Glucocorticoid target elements on CXCL9 promoter not defined"]},{"year":2022,"claim":"The breadth of context-specific fibrotic and immune-modulatory effects was unresolved; KO and gain/loss studies defined CXCL9 as directly pro-fibrotic in skin (Col1a1 induction) yet antifibrotic in lung smooth muscle, a Th17-skewing factor via JNK, and an enabler of antitumor responses in ovarian cancer.","evidence":"Cxcl9/Cxcr3-KO bleomycin skin and PH/fibrosis models, NKT coculture, AAV silencing in MASH with phospho-JNK readouts, CXCL9 overexpression in ovarian cancer models","pmids":["36708947","35763380","34461107","35314795"],"confidence":"High","gaps":["Tissue-specific determinants of pro- vs antifibrotic outcome unexplained","JAK1/STAT2 activation in breast cancer cells rests on a single western-blot study without receptor knockdown (low confidence)"]},{"year":2024,"claim":"Post-translational and upstream transcriptional control of CXCL9 activity required clarification; DPP-4 was shown to convert CXCL9 to a CXCR3 antagonist by N-terminal cleavage, and HIF-1α, EZH2, and LIF were identified as repressors whose targeting restores CXCL9 and CD8+ T cell infiltration.","evidence":"DPP-4 cleavage and CXCR3 binding/activation assays with N-terminal glutamine engineering; HIF-1α and EZH2 knockdown/overexpression with CXCR3 neutralization; LIF blockade in syngeneic and patient-derived tumor models","pmids":["40238455","38484558","39702756","39078728"],"confidence":"High","gaps":["In vivo extent of DPP-4-mediated CXCL9 antagonism not quantified","Hierarchy among HIF-1α, EZH2, and LIF repression in a given tumor not resolved"]},{"year":null,"claim":"How CXCL9 produces opposite fibrotic outcomes in different tissues through a single CXCR3 receptor, and the structural/signaling determinants distinguishing its angiostatic VEGF-sequestering function from its chemotactic GPCR signaling, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of CXCL9-CXCR3 vs CXCL9-VEGF interaction","Cell-context-dependent CXCR3 signaling branches not mechanistically separated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,5,26]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,5,15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,6,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,18,19]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,1,27]}],"complexes":[],"partners":["CXCR3","VEGFA","DPP4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07325","full_name":"C-X-C motif chemokine 9","aliases":["Gamma-interferon-induced monokine","Monokine induced by interferon-gamma","HuMIG","MIG","Small-inducible cytokine B9"],"length_aa":125,"mass_kda":14.0,"function":"Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q07325/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL9","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL9","total_profiled":1310},"omim":[{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"},{"mim_id":"615439","title":"MACULAR DEGENERATION, AGE-RELATED, 13; ARMD13","url":"https://www.omim.org/entry/615439"},{"mim_id":"612923","title":"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3","url":"https://www.omim.org/entry/612923"},{"mim_id":"610984","title":"COMPLEMENT FACTOR I DEFICIENCY; CFID","url":"https://www.omim.org/entry/610984"},{"mim_id":"604378","title":"BECLIN 1; BECN1","url":"https://www.omim.org/entry/604378"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":290.0}],"url":"https://www.proteinatlas.org/search/CXCL9"},"hgnc":{"alias_symbol":["SCYB9","Humig","crg-10"],"prev_symbol":["CMK","MIG"]},"alphafold":{"accession":"Q07325","domains":[{"cath_id":"2.40.50.40","chopping":"32-121","consensus_level":"high","plddt":91.3576,"start":32,"end":121}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07325","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07325-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07325-F1-predicted_aligned_error_v6.png","plddt_mean":87.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL9","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL9"},"sequence":{"accession":"Q07325","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07325.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07325/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07325"}},"corpus_meta":[{"pmid":"29207310","id":"PMC_29207310","title":"CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29207310","citation_count":1199,"is_preprint":false},{"pmid":"9064356","id":"PMC_9064356","title":"Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9064356","citation_count":976,"is_preprint":false},{"pmid":"9060447","id":"PMC_9060447","title":"Mig and IP-10: CXC chemokines that target lymphocytes.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9060447","citation_count":655,"is_preprint":false},{"pmid":"31636098","id":"PMC_31636098","title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31636098","citation_count":590,"is_preprint":false},{"pmid":"37535729","id":"PMC_37535729","title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37535729","citation_count":491,"is_preprint":false},{"pmid":"7595201","id":"PMC_7595201","title":"Human Mig chemokine: biochemical and functional characterization.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7595201","citation_count":315,"is_preprint":false},{"pmid":"20487305","id":"PMC_20487305","title":"Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.","date":"2010","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20487305","citation_count":237,"is_preprint":false},{"pmid":"27490802","id":"PMC_27490802","title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.","date":"2016","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27490802","citation_count":220,"is_preprint":false},{"pmid":"29893515","id":"PMC_29893515","title":"CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29893515","citation_count":166,"is_preprint":false},{"pmid":"8476424","id":"PMC_8476424","title":"HuMig: a new human member of the chemokine family of cytokines.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8476424","citation_count":164,"is_preprint":false},{"pmid":"17513299","id":"PMC_17513299","title":"The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17513299","citation_count":150,"is_preprint":false},{"pmid":"19344719","id":"PMC_19344719","title":"Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19344719","citation_count":143,"is_preprint":false},{"pmid":"27966526","id":"PMC_27966526","title":"Osteoblasts secrete Cxcl9 to regulate angiogenesis in bone.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27966526","citation_count":124,"is_preprint":false},{"pmid":"16819504","id":"PMC_16819504","title":"Evidence that MIG-6 is a tumor-suppressor gene.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16819504","citation_count":109,"is_preprint":false},{"pmid":"16618541","id":"PMC_16618541","title":"MIG-10/lamellipodin and AGE-1/PI3K promote axon guidance and outgrowth in response to slit and netrin.","date":"2006","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/16618541","citation_count":107,"is_preprint":false},{"pmid":"2665839","id":"PMC_2665839","title":"Growth and differentiation of a human megakaryoblastic cell line, CMK.","date":"1989","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2665839","citation_count":105,"is_preprint":false},{"pmid":"33637602","id":"PMC_33637602","title":"CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33637602","citation_count":104,"is_preprint":false},{"pmid":"10589690","id":"PMC_10589690","title":"Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis.","date":"1999","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10589690","citation_count":102,"is_preprint":false},{"pmid":"20351267","id":"PMC_20351267","title":"Mig-6 controls EGFR trafficking and suppresses gliomagenesis.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20351267","citation_count":99,"is_preprint":false},{"pmid":"38518770","id":"PMC_38518770","title":"CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38518770","citation_count":87,"is_preprint":false},{"pmid":"19439667","id":"PMC_19439667","title":"Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19439667","citation_count":82,"is_preprint":false},{"pmid":"29690901","id":"PMC_29690901","title":"CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29690901","citation_count":78,"is_preprint":false},{"pmid":"11752021","id":"PMC_11752021","title":"IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide.","date":"2002","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/11752021","citation_count":78,"is_preprint":false},{"pmid":"17351343","id":"PMC_17351343","title":"Mig-6, signal transduction, stress response and cancer.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17351343","citation_count":76,"is_preprint":false},{"pmid":"21303517","id":"PMC_21303517","title":"Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.","date":"2011","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21303517","citation_count":72,"is_preprint":false},{"pmid":"27576738","id":"PMC_27576738","title":"Interleukin-6, MCP-1, IP-10, and MIG are sequentially expressed in cerebrospinal fluid after subarachnoid hemorrhage.","date":"2016","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27576738","citation_count":67,"is_preprint":false},{"pmid":"12740040","id":"PMC_12740040","title":"SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.","date":"2003","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12740040","citation_count":66,"is_preprint":false},{"pmid":"35314795","id":"PMC_35314795","title":"CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35314795","citation_count":61,"is_preprint":false},{"pmid":"37395276","id":"PMC_37395276","title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37395276","citation_count":60,"is_preprint":false},{"pmid":"30410928","id":"PMC_30410928","title":"AC-YVAD-CMK Inhibits Pyroptosis and Improves Functional Outcome after Intracerebral Hemorrhage.","date":"2018","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/30410928","citation_count":55,"is_preprint":false},{"pmid":"31216458","id":"PMC_31216458","title":"CXCR3-CXCL9: It's All in the Tumor.","date":"2019","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31216458","citation_count":53,"is_preprint":false},{"pmid":"12368204","id":"PMC_12368204","title":"The role of MIG/CXCL9 in cardiac allograft vasculopathy.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12368204","citation_count":52,"is_preprint":false},{"pmid":"28253295","id":"PMC_28253295","title":"Tissue-specific regulation of CXCL9/10/11 chemokines in keratinocytes: Implications for oral inflammatory disease.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28253295","citation_count":51,"is_preprint":false},{"pmid":"37937817","id":"PMC_37937817","title":"The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment.","date":"2024","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37937817","citation_count":50,"is_preprint":false},{"pmid":"35763380","id":"PMC_35763380","title":"Impairment of the NKT-STAT1-CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis.","date":"2022","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35763380","citation_count":49,"is_preprint":false},{"pmid":"12473267","id":"PMC_12473267","title":"IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver.","date":"2002","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12473267","citation_count":49,"is_preprint":false},{"pmid":"28450066","id":"PMC_28450066","title":"Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28450066","citation_count":46,"is_preprint":false},{"pmid":"22701735","id":"PMC_22701735","title":"Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22701735","citation_count":45,"is_preprint":false},{"pmid":"35352167","id":"PMC_35352167","title":"CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/35352167","citation_count":41,"is_preprint":false},{"pmid":"23975214","id":"PMC_23975214","title":"IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome.","date":"2013","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/23975214","citation_count":41,"is_preprint":false},{"pmid":"32060845","id":"PMC_32060845","title":"The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060845","citation_count":39,"is_preprint":false},{"pmid":"12598219","id":"PMC_12598219","title":"Increased IP-10 and MIG expression after intra-amniotic endotoxin in preterm lamb lung.","date":"2003","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12598219","citation_count":39,"is_preprint":false},{"pmid":"19029086","id":"PMC_19029086","title":"Regulation of CXCL9/10/11 in oral keratinocytes and fibroblasts.","date":"2008","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19029086","citation_count":38,"is_preprint":false},{"pmid":"35232969","id":"PMC_35232969","title":"Loss of MIG-6 results in endometrial progesterone resistance via ERBB2.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35232969","citation_count":37,"is_preprint":false},{"pmid":"31699671","id":"PMC_31699671","title":"The Role of CXCL13 and CXCL9 in Early Breast Cancer.","date":"2019","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31699671","citation_count":37,"is_preprint":false},{"pmid":"31913856","id":"PMC_31913856","title":"CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31913856","citation_count":37,"is_preprint":false},{"pmid":"32827461","id":"PMC_32827461","title":"Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32827461","citation_count":37,"is_preprint":false},{"pmid":"26892362","id":"PMC_26892362","title":"Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26892362","citation_count":36,"is_preprint":false},{"pmid":"31352322","id":"PMC_31352322","title":"Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31352322","citation_count":36,"is_preprint":false},{"pmid":"19157479","id":"PMC_19157479","title":"HBx protein induces expression of MIG and increases migration of leukocytes through activation of NF-kappaB.","date":"2009","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/19157479","citation_count":36,"is_preprint":false},{"pmid":"36472587","id":"PMC_36472587","title":"CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/36472587","citation_count":33,"is_preprint":false},{"pmid":"31783271","id":"PMC_31783271","title":"CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis.","date":"2019","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31783271","citation_count":31,"is_preprint":false},{"pmid":"34865465","id":"PMC_34865465","title":"Highly Sensitive Immuno-CRISPR Assay for CXCL9 Detection.","date":"2021","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34865465","citation_count":30,"is_preprint":false},{"pmid":"11238618","id":"PMC_11238618","title":"Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11238618","citation_count":29,"is_preprint":false},{"pmid":"30393811","id":"PMC_30393811","title":"CXCL9 chemokine in ulcerative colitis.","date":"2018","source":"La Clinica terapeutica","url":"https://pubmed.ncbi.nlm.nih.gov/30393811","citation_count":28,"is_preprint":false},{"pmid":"34461107","id":"PMC_34461107","title":"MIG/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg/Th17 balance.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34461107","citation_count":28,"is_preprint":false},{"pmid":"32181005","id":"PMC_32181005","title":"Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/CXCR3 Axis: A Review.","date":"2020","source":"Oman medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32181005","citation_count":28,"is_preprint":false},{"pmid":"29277541","id":"PMC_29277541","title":"HPV16E7-Induced Hyperplasia Promotes CXCL9/10 Expression and Induces CXCR3+ T-Cell Migration to Skin.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29277541","citation_count":26,"is_preprint":false},{"pmid":"26199110","id":"PMC_26199110","title":"Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.","date":"2015","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/26199110","citation_count":25,"is_preprint":false},{"pmid":"36504808","id":"PMC_36504808","title":"CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36504808","citation_count":25,"is_preprint":false},{"pmid":"39447386","id":"PMC_39447386","title":"Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39447386","citation_count":23,"is_preprint":false},{"pmid":"25575814","id":"PMC_25575814","title":"MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25575814","citation_count":23,"is_preprint":false},{"pmid":"16899238","id":"PMC_16899238","title":"mig-5/Dsh controls cell fate determination and cell migration in C. elegans.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16899238","citation_count":22,"is_preprint":false},{"pmid":"39190494","id":"PMC_39190494","title":"CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39190494","citation_count":22,"is_preprint":false},{"pmid":"31285802","id":"PMC_31285802","title":"Urinary CXCL9 and CXCL10 Levels and Acute Renal Graft Rejection.","date":"2019","source":"International journal of organ transplantation medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31285802","citation_count":20,"is_preprint":false},{"pmid":"36708947","id":"PMC_36708947","title":"CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in Fibroblasts.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36708947","citation_count":20,"is_preprint":false},{"pmid":"29228003","id":"PMC_29228003","title":"A MIG-15/JNK-1 MAP kinase cascade opposes RPM-1 signaling in synapse formation and learning.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29228003","citation_count":20,"is_preprint":false},{"pmid":"23502337","id":"PMC_23502337","title":"Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata.","date":"2013","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/23502337","citation_count":19,"is_preprint":false},{"pmid":"23209429","id":"PMC_23209429","title":"MIG-10 functions with ABI-1 to mediate the UNC-6 and SLT-1 axon guidance signaling pathways.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23209429","citation_count":19,"is_preprint":false},{"pmid":"21937599","id":"PMC_21937599","title":"MIG-15 and ERM-1 promote growth cone directional migration in parallel to UNC-116 and WVE-1.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21937599","citation_count":19,"is_preprint":false},{"pmid":"31929430","id":"PMC_31929430","title":"CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.","date":"2020","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/31929430","citation_count":18,"is_preprint":false},{"pmid":"17163262","id":"PMC_17163262","title":"Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study.","date":"2006","source":"Clinical drug investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17163262","citation_count":17,"is_preprint":false},{"pmid":"23241877","id":"PMC_23241877","title":"Cutaneous tumors cease CXCL9/Mig production as a result of IFN-γ-mediated immunoediting.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23241877","citation_count":17,"is_preprint":false},{"pmid":"39078728","id":"PMC_39078728","title":"Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39078728","citation_count":16,"is_preprint":false},{"pmid":"23600831","id":"PMC_23600831","title":"Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.","date":"2013","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23600831","citation_count":16,"is_preprint":false},{"pmid":"36355429","id":"PMC_36355429","title":"Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36355429","citation_count":16,"is_preprint":false},{"pmid":"28925396","id":"PMC_28925396","title":"MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28925396","citation_count":16,"is_preprint":false},{"pmid":"37542661","id":"PMC_37542661","title":"CXCL9 and its Receptor CXCR3, an Important Link Between Inflammation and Cardiovascular Risks in RA Patients.","date":"2023","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37542661","citation_count":15,"is_preprint":false},{"pmid":"27462879","id":"PMC_27462879","title":"The CaM Kinase CMK-1 Mediates a Negative Feedback Mechanism Coupling the C. elegans Glutamate Receptor GLR-1 with Its Own Transcription.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27462879","citation_count":15,"is_preprint":false},{"pmid":"36696410","id":"PMC_36696410","title":"Ac-YVAD-cmk ameliorated sevoflurane-induced cognitive dysfunction and revised mitophagy impairment.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36696410","citation_count":14,"is_preprint":false},{"pmid":"38484558","id":"PMC_38484558","title":"HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, -10 and -11.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38484558","citation_count":14,"is_preprint":false},{"pmid":"25702175","id":"PMC_25702175","title":"CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis.","date":"2015","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/25702175","citation_count":14,"is_preprint":false},{"pmid":"33470761","id":"PMC_33470761","title":"Ac-FLTD-CMK inhibits pyroptosis and exerts neuroprotective effect in a mice model of traumatic brain injury.","date":"2021","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/33470761","citation_count":14,"is_preprint":false},{"pmid":"25976672","id":"PMC_25976672","title":"Mig-6 regulates endometrial genes involved in cell cycle and progesterone signaling.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25976672","citation_count":14,"is_preprint":false},{"pmid":"27671889","id":"PMC_27671889","title":"Antimicrobial activity and regulation of CXCL9 and CXCL10 in oral keratinocytes.","date":"2016","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27671889","citation_count":14,"is_preprint":false},{"pmid":"40238455","id":"PMC_40238455","title":"Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40238455","citation_count":13,"is_preprint":false},{"pmid":"32552717","id":"PMC_32552717","title":"Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32552717","citation_count":13,"is_preprint":false},{"pmid":"36569039","id":"PMC_36569039","title":"CXCL9-11 chemokines and CXCR3 receptor in teleost fish species.","date":"2022","source":"Fish and shellfish immunology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36569039","citation_count":12,"is_preprint":false},{"pmid":"38342608","id":"PMC_38342608","title":"Pharmacological Polarization of Tumor-Associated Macrophages Toward a CXCL9 Antitumor Phenotype.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38342608","citation_count":12,"is_preprint":false},{"pmid":"12792744","id":"PMC_12792744","title":"Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects.","date":"2003","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/12792744","citation_count":12,"is_preprint":false},{"pmid":"38655660","id":"PMC_38655660","title":"Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/38655660","citation_count":12,"is_preprint":false},{"pmid":"21167783","id":"PMC_21167783","title":"Mycobacterium tuberculosis increases IP-10 and MIG protein despite inhibition of IP-10 and MIG transcription.","date":"2010","source":"Tuberculosis (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/21167783","citation_count":12,"is_preprint":false},{"pmid":"31696912","id":"PMC_31696912","title":"Rheumatoid arthritis and the Th1 chemokine MIG.","date":"2019","source":"La Clinica terapeutica","url":"https://pubmed.ncbi.nlm.nih.gov/31696912","citation_count":11,"is_preprint":false},{"pmid":"27910070","id":"PMC_27910070","title":"Mig-6 Mouse Model of Endometrial Cancer.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27910070","citation_count":11,"is_preprint":false},{"pmid":"31550444","id":"PMC_31550444","title":"Inhibiting expression of Cxcl9 promotes angiogenesis in MSCs-HUVECs co-culture.","date":"2019","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/31550444","citation_count":11,"is_preprint":false},{"pmid":"29843645","id":"PMC_29843645","title":"MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29843645","citation_count":11,"is_preprint":false},{"pmid":"36898851","id":"PMC_36898851","title":"EBV-positive pyothorax-associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3.","date":"2023","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/36898851","citation_count":11,"is_preprint":false},{"pmid":"39702756","id":"PMC_39702756","title":"EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39702756","citation_count":11,"is_preprint":false},{"pmid":"23842811","id":"PMC_23842811","title":"MIG: Multi-Image Genome viewer.","date":"2013","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23842811","citation_count":11,"is_preprint":false},{"pmid":"33640906","id":"PMC_33640906","title":"Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.","date":"2021","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/33640906","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53696,"output_tokens":8280,"usd":0.142644,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17725,"output_tokens":4973,"usd":0.106475,"stage2_stop_reason":"end_turn"},"total_usd":0.249119,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CXCL9 (Mig) signals through the CXCR3 receptor, a G-protein coupled receptor selectively expressed on IL-2-activated T lymphocytes; binding mediates Ca2+ mobilization and chemotaxis specifically in activated T cells but not in resting T cells, B cells, monocytes, or granulocytes.\",\n      \"method\": \"Receptor cloning, Ca2+ flux assay, chemotaxis assay, expression profiling by Northern/flow cytometry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — receptor cloned and functionally characterized with multiple orthogonal methods (Ca2+ mobilization, chemotaxis, selectivity panel); replicated by independent groups\",\n      \"pmids\": [\"9064356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Recombinant human CXCL9 (Mig) induces transient elevation of intracellular Ca2+ and is chemotactic for activated T lymphocytes and tumor-infiltrating lymphocytes, but not for neutrophils or monocytes; secreted CXCL9 exists as multiple species due to proteolytic cleavage at basic carboxy-terminal residues occurring intracellularly before secretion, and carboxy-terminal truncation reduces specific activity.\",\n      \"method\": \"CHO cell expression/purification, Ca2+ flux assay, modified Boyden chamber chemotaxis assay, SDS-PAGE, N-terminal sequencing\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — recombinant protein biochemistry with multiple orthogonal assays; activity-structure relationship established by truncation analysis\",\n      \"pmids\": [\"7595201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CXCL9 (HuMig) is induced in human monocytic cells (THP-1) and peripheral blood mononuclear cells by IFN-γ but not by IFN-α or LPS, establishing IFN-γ as the primary transcriptional inducer.\",\n      \"method\": \"cDNA library screening, Northern blot, cytokine stimulation assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single lab, multiple stimuli tested with Northern blot, clearly delineating IFN-γ specificity\",\n      \"pmids\": [\"8476424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CXCL9 and IP-10/CXCL10 share the CXCR3 receptor, show reciprocal desensitization on activated T cells, inhibit neovascularization, inhibit hematopoietic progenitor cells, and exert anti-tumor effects in vitro and in vivo.\",\n      \"method\": \"Receptor cross-desensitization assay, in vitro angiogenesis inhibition assay, in vivo tumor models\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple activities demonstrated with orthogonal methods in a single review/experimental paper, replicated across two chemokines\",\n      \"pmids\": [\"9060447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL9 exerts direct antifibrotic effects on human hepatic stellate cells (LX-2) by suppressing collagen production; CXCR3-deficient mice show increased liver fibrosis associated with decreased intrahepatic IFN-γ-positive T cells and reduced IFN-γ mRNA, indicating that CXCL9-CXCR3 regulates Th1-associated antifibrotic immune pathways in the liver.\",\n      \"method\": \"In vitro stellate cell stimulation (collagen production assay), CXCR3 knockout mouse model of liver fibrosis, intrahepatic immune cell subset analysis, IFN-γ mRNA measurement\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro direct cellular assay plus in vivo KO model with defined cellular and molecular phenotype readouts\",\n      \"pmids\": [\"19344719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Osteoblast-secreted CXCL9 acts as an angiostatic factor by interacting with VEGF and preventing its binding to endothelial cells and osteoblasts, thereby abrogating angiogenesis and osteogenesis in bone marrow; mTORC1 activates CXCL9 expression in osteoblasts by transcriptional upregulation of STAT1, which increases STAT1 binding to the Cxcl9 promoter.\",\n      \"method\": \"Mouse bone marrow model, in vitro VEGF binding competition assay, STAT1 ChIP assay, mTORC1 signaling inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic pathway defined by multiple orthogonal methods: protein interaction (VEGF binding), promoter ChIP, in vivo and in vitro loss-of-function\",\n      \"pmids\": [\"27966526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CXCL9 (MIG) plays a functionally required role in CD4+ T lymphocyte recruitment in cardiac allograft vasculopathy (CAV); macrophages (MOMA-2+) are the predominant source of CXCL9 in this context, and antibody neutralization of CXCL9 significantly reduces CD4+ T cell infiltration and intimal thickening.\",\n      \"method\": \"MHC II-mismatched murine cardiac transplant model, antibody neutralization, immunohistochemistry, gene expression profiling\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo neutralization with defined cellular phenotype, macrophage source identified by immunostaining, replicated mechanistic conclusion\",\n      \"pmids\": [\"12368204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCL9 (MIG) and CXCL10 (IP-10) are required for SLC/CCL21-mediated antitumor responses; in vivo depletion of either chemokine reduces antitumor efficacy, CXCR3+ T cell frequency, and CD11c+ DC accumulation at the tumor site, revealing interdependence among IFN-γ, CXCL9, and CXCL10 in antitumor immunity.\",\n      \"method\": \"In vivo antibody depletion/neutralization, flow cytometry, cytokine/chemokine measurement at tumor site\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo neutralization with defined cellular readouts, single lab\",\n      \"pmids\": [\"12740040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Hepatitis B virus HBx protein induces CXCL9 (MIG) expression in a dose-dependent manner via direct NF-κB binding to the MIG promoter at position -147, as demonstrated by luciferase reporter, ChIP, and EMSA; increased CXCL9 protein levels enhance migration of peripheral blood lymphocytes, an effect blocked by NF-κB inhibition.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), chemotaxis assay, NF-κB inhibition\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter mechanism established by three orthogonal molecular methods (luciferase, ChIP, EMSA) in single lab\",\n      \"pmids\": [\"19157479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In the virus-infected liver (adenovirus hepatitis model), IFN-γ induces CXCL9 (MIG) and IP-10 in hepatocytes; optimal induction requires a co-stimulatory signal from Fas cross-linking on hepatocytes; NK/T cells expressing NK1.1 and AsGM1 provide both signals; antibody-mediated ablation of NK/T cells inhibits IFN-γ and chemokine transcript induction. T cell (but not NK cell) chemotaxis by hepatocyte supernatants was abrogated by anti-Mig and anti-Crg-2 antibodies.\",\n      \"method\": \"Murine adenovirus hepatitis model, NK/T cell depletion, anti-Fas antibody injection, neutralizing antibody chemotaxis inhibition assay\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo depletion and in vitro neutralization with defined cellular/molecular readouts, single lab\",\n      \"pmids\": [\"12473267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-γ plus TNF-α induces CXCL9 (MIG) expression in human mesangial cells; NO donors suppress this induction through cGMP-independent inhibition of NF-κB activation, as shown by EMSA.\",\n      \"method\": \"Primary human mesangial cell culture, cytokine stimulation, EMSA, NO donor treatment, immunostaining\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA identifies NF-κB as the transcriptional mediator; mechanistic pathway established by pharmacological inhibition and molecular assay, single lab\",\n      \"pmids\": [\"11752021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CXCL9 (MIG) and CXCL10 (IP-10), signaling through CXCR3 expressed on mesangial cells, directly induce proliferation of human mesangial cells, revealing a non-immune direct cellular effect of these chemokines.\",\n      \"method\": \"CXCR3 expression by flow cytometry, Ca2+ flux assay, cell proliferation assay with recombinant chemokines\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional receptor expression confirmed by flow cytometry, proliferative effect directly demonstrated in vitro, single lab\",\n      \"pmids\": [\"10589690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"M. tuberculosis inhibits IFN-γ-induced CXCL9 (MIG) transcription by disrupting STAT1α binding to cis-regulatory elements in the MIG promoter, partially via NF-κB and p38 MAPK pathways; paradoxically, combined IFN-γ and MTB stimulation increases MIG protein through post-transcriptional mechanisms involving NF-κB and p38 MAPK.\",\n      \"method\": \"STAT1 EMSA on MIG promoter elements, kinase inhibitor studies, RT-PCR, ELISA protein measurement\",\n      \"journal\": \"Tuberculosis (Edinburgh, Scotland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA identifies transcriptional mechanism, inhibitor studies delineate signaling pathway, single lab\",\n      \"pmids\": [\"21167783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Progranulin (PGRN) inhibits TNF- and IFN-γ-induced CXCL9 and CXCL10 expression, and this inhibitory effect depends on TNFR1 signaling, as demonstrated by gene array analysis in PGRN-null mice and recombinant PGRN protein treatment experiments.\",\n      \"method\": \"Gene array on PGRN KO vs. WT CD4+ T cells, recombinant PGRN treatment, TNFR1-dependent rescue experiments, dermatitis model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse plus recombinant protein rescue, TNFR1 dependency shown, single lab\",\n      \"pmids\": [\"26892362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-27 induces CXCL9, CXCL10, and CXCL11 expression in hepatic cells in a STAT1-dependent manner; during ConA-induced hepatitis, IL-27 and IFN-γ cooperatively regulate CXCR3 ligand expression, with IFN-γ KO abolishing upregulation.\",\n      \"method\": \"In vitro cytokine stimulation (human hepatic cell lines and primary cells), in vivo ConA hepatitis model, IL-27 neutralization, IFN-γ KO mice, RT-PCR, ELISA\",\n      \"journal\": \"Journal of molecular medicine (Berlin, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo with KO and neutralization, STAT1-dependence established, single lab\",\n      \"pmids\": [\"26199110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Macrophages are the predominant cellular source of CXCL9 following dual PD-1/CTLA-4 immune checkpoint blockade; macrophage depletion abrogates CD8+ T cell infiltration and therapeutic efficacy, establishing macrophage-derived CXCL9 as functionally required for ICB antitumor responses.\",\n      \"method\": \"NanoString analysis, flow cytometry, cytometric bead array, antibody depletion, single-cell RNA-seq, murine tumor models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — macrophage depletion with defined functional readout, validated in both murine models and human patient scRNA-seq data, multiple orthogonal methods\",\n      \"pmids\": [\"31636098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9 directly induces Col1a1 (collagen type I) mRNA expression in murine fibroblasts via CXCR3; fibrosis in a bleomycin skin model is dependent on CXCL9 and CXCR3 (not CXCL10), as shown by chemokine- and receptor-deficient mouse experiments.\",\n      \"method\": \"Cxcl9-KO, Cxcl10-KO, Cxcr3-KO mouse bleomycin fibrosis model, recombinant CXCL9 stimulation of fibroblasts, Col1a1 mRNA quantification, REX3 reporter mice\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — KO mice with specific phenotype readout, direct recombinant protein stimulation assay, chemokine-specific (CXCL9 not CXCL10) distinction established\",\n      \"pmids\": [\"36708947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9 promotes Th17 cell proliferation and skews the Treg/Th17 balance toward Th17 in a JNK-dependent manner; AAV-mediated silencing of CXCL9 in a murine MASH model reduces Th17 frequency and phospho-JNK levels, while CXCL9 overexpression has the opposite effect.\",\n      \"method\": \"Recombinant adeno-associated virus gene transfer/silencing, T cell differentiation assays, phospho-JNK western blot, JNK inhibitor experiments, murine MASH model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo AAV manipulation with defined cellular phenotype plus in vitro mechanistic follow-up, single lab\",\n      \"pmids\": [\"34461107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9 signaling through CXCR3 activates the JAK1/STAT2 pathway in triple-negative breast cancer cells; CXCL9 overexpression increases JAK1/STAT2 phosphorylation as shown by western blot.\",\n      \"method\": \"CXCL9 overexpression in MDA-MB-231 cells, western blot for JAK1/STAT2 phosphorylation\",\n      \"journal\": \"Cancer immunology, immunotherapy : CII\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (western blot) in single cell line, no receptor knockdown validation\",\n      \"pmids\": [\"36472587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL9/10/11 signaling through CXCR3 upregulates PD-L1 expression in gastric cancer cells by activating STAT3 and Akt (PI3K-Akt) pathways; blocking CXCR3 signaling abolishes PD-L1 upregulation and phosphorylation of STAT3 and Akt.\",\n      \"method\": \"Western blot, gastric cancer cell line treatment with recombinant CXCL9/10/11, CXCR3 blocking, in vivo tumor experiments\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor blocking plus pathway western blot in vitro and in vivo confirmation, single lab\",\n      \"pmids\": [\"29690901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9 overexpression in murine ovarian cancer (ID8) models results in T-cell accumulation, delayed ascites formation, and improved survival dependent on adaptive immune function; in ICB-resistant models, CXCL9 is sufficient to enable successful anti-PD-L1 therapy.\",\n      \"method\": \"Murine ovarian cancer models with CXCL9 overexpression, immune depletion experiments, survival analysis, flow cytometry\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss/gain of function with defined cellular and survival readouts, single lab\",\n      \"pmids\": [\"35314795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL9 inhibits collagen deposition in human pulmonary arterial smooth muscle cells (hPASMCs) via CXCR3, and pharmacological NKT cell activation restores CXCL9 production and ameliorates vascular remodeling in a mouse PH/fibrosis model via the STAT1-CXCL9-CXCR3 axis; CXCL10 did not share this antifibrotic effect.\",\n      \"method\": \"NKT cell coculture with hPASMCs, secretome analysis, CXCL9 recombinant protein treatment, CXCR3 inhibition, murine PH/fibrosis model with pharmacological NKT activation (KRN7000)\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro recombinant protein assay plus in vivo pharmacological model with mechanistic readouts, single lab\",\n      \"pmids\": [\"35763380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Prostaglandin E2 (a COX metabolite) acts as a negative regulator of CXCL9 secretion in ovarian cancer cell lines, while COX inhibition by indomethacin (but not celecoxib) significantly upregulates CXCL9; celecoxib suppresses NF-κB activation and inhibits CXCL9 release.\",\n      \"method\": \"Ovarian cancer cell line treatment with PGE2 and COX inhibitors, ELISA for CXCL9/CXCL10, NF-κB activation assay\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological manipulations with defined molecular readouts, single lab\",\n      \"pmids\": [\"27490802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DPP-4 cleaves the two N-terminal amino acids of CXCL9, converting it into a CXCR3 competitive antagonist that retains binding but loses receptor activation; adding an N-terminal glutamine residue to CXCL9-Fc renders it a fully active CXCR3 agonist resistant to DPP-4 cleavage, as demonstrated by biochemical analysis and computational modeling.\",\n      \"method\": \"Biochemical DPP-4 cleavage assay, CXCR3 binding and activation assays, computational modeling, engineering of N-terminal glutamine variant\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay, receptor activation assay, and structure-activity engineering combined in single study\",\n      \"pmids\": [\"40238455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IFN-γ-mediated immune stress imposed by T cells drives tumor cells to epigenetically lose CXCL9/Mig expression (immunoediting); Mig-deficient tumor variants show increased resistance to T cell-mediated immunity; CXCL10 expression does not compensate for absent CXCL9 antitumor function, indicating a non-redundant role for CXCL9.\",\n      \"method\": \"Methylcholanthrene-induced fibrosarcoma and melanoma models, in vivo T cell and IFN-γ immune stress experiments, chemokine expression analysis, tumor growth assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo immune stress model with defined molecular and cellular readouts, non-redundancy established by comparison with CXCL10-expressing variants, single lab\",\n      \"pmids\": [\"23241877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Glucocorticoids suppress CXCL9 and CXCL10 expression directly in renal tubular epithelial cells (not in T cells), resulting in reduced CXCR3+CD4+ T cell recruitment to the inflamed kidney; this CXCL9/CXCL10-CXCR3 axis was identified as a target of glucocorticoid-mediated protection in crescentic glomerulonephritis.\",\n      \"method\": \"In vitro glucocorticoid treatment of renal tubular cells, experimental mouse crescentic glomerulonephritis model, single-cell analysis of kidney biopsies, T cell recruitment assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic in vitro + in vivo with cell-type specific dissection (tubular cells vs T cells), single lab\",\n      \"pmids\": [\"36355429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cxcl9 secreted by osteoblasts during osteogenic differentiation in MSC co-cultures inhibits angiogenesis by suppressing VEGF binding to endothelial cells; mTOR/STAT1 signaling activates Cxcl9 in osteoblasts; blocking this pathway with rapamycin reduces Cxcl9 and restores angiogenesis.\",\n      \"method\": \"MSC-HUVEC co-culture, VEGF binding assay, mTOR/STAT1 inhibition with rapamycin, Cxcl9 knockdown\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic manipulations (KD, inhibitor, binding assay) in co-culture model, single lab\",\n      \"pmids\": [\"31550444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CXCL9, CXCL10, and CCL19 are synergistically required for T cell (CD8+) recruitment in lichen planus; keratinocytes and fibroblasts in LP lesions are identified as cellular sources; an in vitro migration assay demonstrated synergistic enhancement of CD8+ T cell recruitment by CCL19 combined with CXCL9 or CXCL10 beyond any individual cytokine.\",\n      \"method\": \"scRNA-seq on blood and skin, in vitro T cell migration assay with primary human T cells and recombinant cytokines\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — scRNA-seq cell source identification plus direct functional migration assay, single lab\",\n      \"pmids\": [\"39190494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LIF (leukemia inhibitory factor) induced by HPV E6/E7 via NFκB suppresses CXCL9 expression in tumor-associated macrophages; LIF blockade promotes CXCL9 induction and CD8+ T cell infiltration, sensitizing tumors to immune checkpoint inhibitors.\",\n      \"method\": \"Primary pDC and macrophage cultures, LIF blockade experiments, syngeneic animal models, patient-derived models, flow cytometry for CD8+ T cells\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — macrophage-specific CXCL9 suppression by LIF demonstrated in vitro and in vivo, pathway (E6/E7 → NFκB → LIF → CXCL9 suppression) established, single lab\",\n      \"pmids\": [\"39078728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HIF-1α suppresses CXCL9 (and CXCL10, CXCL11) expression in colorectal cancer; HIF-1α knockdown or overexpression respectively increases or decreases these chemokines in vitro; in vivo BIRC2/HIF-1α inhibition promotes CD8+ T cell infiltration via the CXCL9/CXCL10/CXCL11-CXCR3 axis, and this is reversed by CXCR3 neutralization.\",\n      \"method\": \"HIF-1α knockdown/overexpression in CRC cell lines, CXCR3 neutralizing antibody in vivo, xenograft/syngeneic mouse models, flow cytometry\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional manipulation (KD and OE) plus in vivo CXCR3 neutralization epistasis, single lab\",\n      \"pmids\": [\"38484558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EZH2 in tumor cells suppresses CXCL9 expression by repressing NF-κB-mediated CXCL9 transcriptional activation; EZH2 targeting restores CXCL9 expression and enhances CD8+ T cell infiltration into the tumor microenvironment of esophageal squamous cell carcinoma.\",\n      \"method\": \"EZH2 KD/inhibition, NF-κB pathway analysis, CXCL9 promoter regulation, CD8+ T cell infiltration assays in vivo and in vitro\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EZH2-NF-κB-CXCL9 transcriptional mechanism identified with functional downstream readout, single lab\",\n      \"pmids\": [\"39702756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCL9 has direct antimicrobial activity against Streptococcus sanguinis and E. coli as demonstrated by radial diffusion assay; CXCL9 mRNA is absent in unstimulated oral keratinocytes but strongly induced by IFN-γ, whereas CXCL10 is constitutively expressed and enhanced by LPS.\",\n      \"method\": \"Radial diffusion antimicrobial assay, mRNA expression profiling by PCR with various stimuli (IFN-γ, LPS)\",\n      \"journal\": \"European journal of oral sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct antimicrobial assay with two bacterial species; differential induction pattern established, single lab\",\n      \"pmids\": [\"27671889\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL9 is an IFN-γ-inducible CXC chemokine that signals exclusively through the CXCR3 receptor (a Gαi-coupled GPCR) to mobilize intracellular Ca2+ and drive chemotaxis of activated CD4+ and CD8+ T cells, NK cells, and tumor-infiltrating lymphocytes, while leaving resting lymphocytes, neutrophils, and monocytes unresponsive; it is produced predominantly by macrophages, fibroblasts, and epithelial cells in inflammatory contexts, with its expression transcriptionally activated by IFN-γ via STAT1, augmented by TNF-α via NF-κB, suppressed by PGE2/COX, HIF-1α, EZH2, LIF, and MTB-mediated STAT1 displacement, and post-translationally truncated by DPP-4 (converting it to a CXCR3 antagonist); mechanistic studies have further defined direct antifibrotic actions in hepatic stellate cells, angiostatic activity through VEGF competition, pro-fibrotic Col1a1 induction in dermal fibroblasts via CXCR3, direct antimicrobial activity, and modulation of Th17/Treg balance via JNK signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CXCL9 is an IFN-γ-inducible CXC chemokine that orchestrates the recruitment of activated T lymphocytes to inflamed and tumor tissues by signaling exclusively through the CXCR3 receptor, a G-protein-coupled receptor selectively expressed on IL-2-activated T cells, where ligand binding mobilizes intracellular Ca2+ and drives chemotaxis of activated T cells and tumor-infiltrating lymphocytes while leaving resting T cells, B cells, monocytes, and granulocytes unresponsive [#0, #1]. Its expression is transcriptionally driven by IFN-γ as the primary inducer [#2], operating through STAT1 binding to the CXCL9 promoter [#5, #14] and through NF-κB, which can be engaged by viral HBx protein and is suppressed by nitric oxide donors [#8, #10]; this transcriptional output is repressed by HIF-1α, EZH2, LIF, prostaglandin E2/COX activity, and by M. tuberculosis-mediated displacement of STAT1 from cis-regulatory elements [#12, #22, #28, #29, #30]. Functionally, CXCL9 is non-redundant with the co-receptor ligand CXCL10 in driving antitumor immunity: macrophage-derived CXCL9 is required for CD8+ T cell infiltration and the efficacy of immune checkpoint blockade, and tumors epigenetically silence CXCL9 to escape T cell-mediated control [#15, #24, #28]. Beyond leukocyte trafficking, CXCL9 exerts direct, CXCR3-dependent effects on non-immune cells: it is angiostatic by competitively blocking VEGF binding to endothelial cells [#5, #26], it directly modulates fibrosis—suppressing collagen in hepatic stellate cells and pulmonary arterial smooth muscle cells yet inducing Col1a1 in dermal fibroblasts [#4, #16, #21]—and it skews the Treg/Th17 balance toward Th17 in a JNK-dependent manner [#17]. CXCL9 also possesses direct antimicrobial activity against bacteria [#31]. Activity is governed post-translationally by N- and C-terminal proteolysis: C-terminal truncation at basic residues reduces specific activity [#1], while DPP-4 cleavage of the two N-terminal residues converts CXCL9 into a CXCR3 competitive antagonist that retains binding but loses receptor activation [#23].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing what stimulus controls CXCL9 expression was needed to place it in an immune pathway; demonstrating selective IFN-γ inducibility defined it as an interferon-effector chemokine.\",\n      \"evidence\": \"cDNA screening and Northern blot of IFN-γ-, IFN-α-, and LPS-stimulated human monocytic cells\",\n      \"pmids\": [\"8476424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the transcription factor mediating IFN-γ induction\", \"Single cell type tested\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Whether CXCL9 was a functional chemoattractant with cellular selectivity was unknown; recombinant protein assays showed it triggers Ca2+ flux and chemotaxis in activated/tumor-infiltrating T cells but not neutrophils or monocytes, and that C-terminal truncation tunes its activity.\",\n      \"evidence\": \"Recombinant CXCL9 from CHO cells, Ca2+ flux, Boyden chamber chemotaxis, SDS-PAGE and N-terminal sequencing\",\n      \"pmids\": [\"7595201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity not established here\", \"Mechanism distinguishing activated from resting T cells unresolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The receptor mediating CXCL9 action was unidentified; cloning CXCR3 and showing its selective expression on IL-2-activated T cells defined the receptor basis for CXCL9's leukocyte selectivity.\",\n      \"evidence\": \"Receptor cloning, Ca2+ flux, chemotaxis, and expression profiling across leukocyte subsets\",\n      \"pmids\": [\"9064356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G-protein coupling details not dissected\", \"Did not address shared ligand usage with other chemokines\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Whether CXCL9 was redundant with CXCL10 and had non-chemotactic functions was open; demonstrating shared CXCR3 usage, reciprocal desensitization, and angiostatic/anti-tumor activity broadened its functional repertoire.\",\n      \"evidence\": \"Receptor cross-desensitization, in vitro angiogenesis inhibition, and in vivo tumor models\",\n      \"pmids\": [\"9060447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of angiostasis not defined\", \"Degree of non-redundancy with CXCL10 unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Transcriptional control beyond IFN-γ and the cellular source in vivo were unclear; mesangial, cardiac allograft, and viral hepatitis studies identified NF-κB as a co-regulator, macrophages/hepatocytes as sources, and a functionally required role in CD4+ T cell recruitment.\",\n      \"evidence\": \"EMSA for NF-κB in cytokine-stimulated mesangial cells, antibody neutralization in murine cardiac transplant and adenovirus hepatitis models with immunostaining\",\n      \"pmids\": [\"11752021\", \"12368204\", \"12473267\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of NF-κB vs STAT1 not resolved\", \"Co-stimulatory Fas requirement mechanism in hepatocytes incompletely defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Whether CXCL9 cooperated with other chemokines in antitumor immunity was untested; depletion showed it is required alongside CXCL10 for CCL21-driven antitumor responses and CXCR3+ T cell/DC accumulation.\",\n      \"evidence\": \"In vivo antibody depletion, flow cytometry, and chemokine measurement at the tumor site\",\n      \"pmids\": [\"12740040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single tumor system\", \"Did not separate CXCL9-specific from CXCL10-specific contributions\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Direct non-immune cellular actions were unproven; stellate cell assays and CXCR3-KO mice established a direct antifibrotic effect and a Th1-associated antifibrotic axis, while HBx studies mapped NF-κB binding to a defined promoter position.\",\n      \"evidence\": \"LX-2 collagen assays, CXCR3-KO liver fibrosis model, and luciferase/ChIP/EMSA mapping of NF-κB at MIG promoter -147\",\n      \"pmids\": [\"19344719\", \"19157479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling driving collagen suppression not detailed\", \"Direct vs IFN-γ-mediated contributions to the in vivo phenotype not fully separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Whether CXCL9 was functionally non-redundant in tumor immunity was unsettled; immunoediting models showed tumors epigenetically lose CXCL9 under IFN-γ/T cell pressure and that CXCL10 cannot compensate.\",\n      \"evidence\": \"Methylcholanthrene fibrosarcoma/melanoma models with T cell and IFN-γ immune stress and chemokine expression analysis\",\n      \"pmids\": [\"23241877\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Epigenetic mechanism of silencing not molecularly defined\", \"Single carcinogen-induced tumor lineage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The mechanism of angiostasis and additional regulatory inputs were unknown; osteoblast studies showed CXCL9 binds VEGF to block its receptor engagement under mTORC1/STAT1 control, PGE2/COX was identified as a negative regulator, and direct antimicrobial activity was demonstrated.\",\n      \"evidence\": \"VEGF binding competition assays, STAT1 ChIP, rapamycin inhibition in bone marrow/MSC models, COX inhibitor and ELISA studies, radial diffusion antimicrobial assays\",\n      \"pmids\": [\"27966526\", \"31550444\", \"27490802\", \"27671889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CXCL9-VEGF interaction not defined\", \"Antimicrobial mechanism (membrane vs receptor) not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Whether CXCR3 signaling in tumor cells had cell-intrinsic consequences was open; gastric cancer studies showed CXCR3 ligands upregulate PD-L1 via STAT3 and PI3K-Akt.\",\n      \"evidence\": \"Recombinant CXCL9/10/11 treatment with CXCR3 blocking and pathway western blots in vitro and in vivo\",\n      \"pmids\": [\"29690901\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CXCL9-specific contribution not isolated from CXCL10/11\", \"Single cancer type\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The therapeutically critical cellular source and a key suppressive input were undefined; checkpoint blockade and glucocorticoid studies identified macrophages as the required CXCL9 source for ICB efficacy and renal tubular epithelium as a glucocorticoid-suppressible source.\",\n      \"evidence\": \"Macrophage depletion with scRNA-seq in murine and human tumor data; cell-type-specific glucocorticoid treatment in renal tubular cells and crescentic glomerulonephritis models\",\n      \"pmids\": [\"31636098\", \"36355429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional program distinguishing macrophage CXCL9 induction not fully mapped\", \"Glucocorticoid target elements on CXCL9 promoter not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The breadth of context-specific fibrotic and immune-modulatory effects was unresolved; KO and gain/loss studies defined CXCL9 as directly pro-fibrotic in skin (Col1a1 induction) yet antifibrotic in lung smooth muscle, a Th17-skewing factor via JNK, and an enabler of antitumor responses in ovarian cancer.\",\n      \"evidence\": \"Cxcl9/Cxcr3-KO bleomycin skin and PH/fibrosis models, NKT coculture, AAV silencing in MASH with phospho-JNK readouts, CXCL9 overexpression in ovarian cancer models\",\n      \"pmids\": [\"36708947\", \"35763380\", \"34461107\", \"35314795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific determinants of pro- vs antifibrotic outcome unexplained\", \"JAK1/STAT2 activation in breast cancer cells rests on a single western-blot study without receptor knockdown (low confidence)\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Post-translational and upstream transcriptional control of CXCL9 activity required clarification; DPP-4 was shown to convert CXCL9 to a CXCR3 antagonist by N-terminal cleavage, and HIF-1α, EZH2, and LIF were identified as repressors whose targeting restores CXCL9 and CD8+ T cell infiltration.\",\n      \"evidence\": \"DPP-4 cleavage and CXCR3 binding/activation assays with N-terminal glutamine engineering; HIF-1α and EZH2 knockdown/overexpression with CXCR3 neutralization; LIF blockade in syngeneic and patient-derived tumor models\",\n      \"pmids\": [\"40238455\", \"38484558\", \"39702756\", \"39078728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo extent of DPP-4-mediated CXCL9 antagonism not quantified\", \"Hierarchy among HIF-1α, EZH2, and LIF repression in a given tumor not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CXCL9 produces opposite fibrotic outcomes in different tissues through a single CXCR3 receptor, and the structural/signaling determinants distinguishing its angiostatic VEGF-sequestering function from its chemotactic GPCR signaling, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of CXCL9-CXCR3 vs CXCL9-VEGF interaction\", \"Cell-context-dependent CXCR3 signaling branches not mechanistically separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 5, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 5, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 6, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 18, 19]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 1, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CXCR3\", \"VEGFA\", \"DPP4\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}